Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
FTY720 hydrochloride (HB3899)
Description:Sphingosine 1-phosphate (S1P) receptor (S1P1, S1P3, S1P4, and S1P5) modulator
Purity:>98%
Haloperidol hydrochloride (HB1842)
Description:Dopamine receptor antagonist with partial D2-like selectivity
Purity:>99%
Linezolid (HB4443)
Description:Inhibits protein synthesis in gram-positive bacteria. Antibiotic.
Purity:>98%
Rapamycin (HB2779)
Description:mTOR inhibitor and potent immunosuppressant. Also used in inducible gene editing methods (e.g. CRISPR/Cas9) and promotes hPSC differentiation.
Purity:>98%
Valproic acid sodium salt (HB0867)
Description:Histone deacetylase inhibitor. Shows multitude of biological actions. Enables pluripotent stem cell induction from somatic cells.